The increase in effective sensitivity and improved spatial resolution led to an improved visibility of small lesions, which is not only important for detection of lesions and metastases in 18F–FDG-PET/CT scans, but also for other tracers, for instance the use of 68Ga-PSMA for the detection of (lymph node) metastases in patients with prostate cancer, 89Zr-MAb immunoPET studies, 90Y imaging for patients who are treated for liver metastasis, or 124I imaging for follow-up of thyroid cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.